Circulating tumour DNA tests for T790M mutations in non-small cell lung cancer

Register an interest in this topic

Topic Status Incomplete

The presence or absence of epidermal growth factor receptor (EGFR) T790M mutations in non-small cell lung cancer indicate which treatments are most likely to be effective. Biopsy of the tumour can be associated with morbidity such as pneumothorax, bleeding and infection. A less invasive alternative to tissue biopsy is to test a blood sample for EGFR T790M mutations in circulating tumour DNA.

Summary

 

Health Technology Wales researchers searched for clinical and cost effectiveness evidence on circulating tumour DNA tests for T790M mutations in people with advanced or metastatic non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.

Topic Exploration Report

TER516 12.2023

Our advice documents are free to download but we would be grateful if you could help us improve our services by telling us why you are looking at our advice.

Skip form and download file Close

    We may like to contact you by email to find out more about how you used the documents.